A CDC advisory committee decided not to vote on how Johnson & Johnson’s COVID-19 vaccine should be deployed, reasoning that it needs more time to review data related to rare blood clots potentially linked to the vaccine.
The CDC and FDA announced on April 13 their recommendation to pause the vaccine’s use on safety grounds.
The Advisory Committee on Immunization Practices (ACIP) could ultimately help the CDC decide whether to continue using the vaccine, constrain it or discontinue it altogether.
Get the full story from our sister site, Drug Discovery & Development.